The latest market price of lenvatinib/lenvatinib in 2025

Lenvatinib is an oral multi-target tyrosine kinase inhibitor that is used to treat a variety of advanced solid tumors, including renal cancer, liver cancer, thyroid cancer and some gynecological malignancies. Its mechanism is to block angiogenesis and tumor signaling pathways at the same time, making cancer cells "starved" and lose their growth environment. With the development of precision medicine, lenvatinib has become one of the important basic drugs for the treatment of various cancers around the world.

In the domestic market, lenvatinib has been included in the national medical insurance directory, which means that patients’ actual payment costs are significantly reduced. Taking the commonly used specification 4mg*30 capsules as an example, the price before medical insurance reimbursement is about RMB 3,000. However, after reimbursement by medical insurance in some provinces and cities, the patient's out-of-pocket price may be as low as less than a thousand yuan. The version sold domestically is provided by Eisai (China) Company, and the drug quality and supply channels comply with national standards.

In the international market, the price of the original drugLenvima is higher. For example, in the United States or Europe, the price of each box may be equivalent to RMB 2,000 to 4,000 yuan; while the price of generic versions from India, Laos or Bangladesh is between 400 and 900 yuan. Due to their lower cost, generic drugs provide more treatment options for patients who cannot afford the high-priced original drugs.

In addition to monotherapy, the combined use of lenvatinib and immune checkpoint inhibitors (such as pembrolizumab) has become a new clinical trend. This "immune + targeting" combination shows better efficacy than single drugs in some tumors. The latest foreign research points out that lenvatinib can enhance the anti-tumor activity of immune drugs and provide more ideas for future cancer treatment.

Overall, lenvatinib is highly competitive in terms of efficacy, safety, and economy. As medical insurance policies continue to improve and the market for generic drugs expands, their prices are expected to drop further in the future, allowing more cancer patients to obtain effective treatment at a reasonable cost.

Reference materials:https://www.lenvima.com/